TAILIEUCHUNG - Effects of sitagliptin as add on blood glucose level in patients with type 2 diabete in national hospital of endocrinology

Objectives: To evaluate effects of dipeptidyl peptidase (DPP)-4 inbibitors sitagliptin as addon therapy on blood glucose in patients with type 2 diabetes inadequately controlled with oral antidiabetic drug (OAD) monotherapy or combination. Subjects and methods: An interventional study was conducted on 101 adult patients with type 2 diabetes inadequately controlled with OAD monotherapy or combination other than DPP-4 inhibitors with HbA1c from 7 to 10%. | Journal of military pharmaco-medicine no4-2018 EFFECTS OF SITAGLIPTIN AS ADD-ON BLOOD GLUCOSE LEVEL IN PATIENTS WITH TYPE 2 DIABETES IN NATIONAL HOSPITAL OF ENDOCRINOLOGY Le Thi Viet Ha*; Doan Van De** SUMMARY Objectives: To evaluate effects of dipeptidyl peptidase (DPP)-4 inbibitors sitagliptin as addon therapy on blood glucose in patients with type 2 diabetes inadequately controlled with oral antidiabetic drug (OAD) monotherapy or combination. Subjects and methods: An interventional study was conducted on 101 adult patients with type 2 diabetes inadequately controlled with OAD monotherapy or combination other than DPP-4 inhibitors with HbA1c from 7 to 10%. The outcome measures were fasting plasma glucose (FPG), 2 hour postprandial glucose (2hPPG) and HbA1c that were assessed at the baseline, after 12 and 24 weeks. A DDP-4 inhibitor was started with a half or full dose for the first 12 weeks and increased to full dose for the last 12 weeks if started as half dose. The other OAD and their doses were kept unchanged during the whole study. Results: The mean age and diabetes duration was ± and ± years, respectively. Before the study, metformin monotherapy was used by of patients and the most used combination was metformin plus sulfonylurea ( mg in all the patients). Sitagliptin was the only used DPP-4 inhibitor with mean dose of mg/day and mg/day for the first and second 12 weeks. After 24 weeks, compared to the baseline, the mean FPG, 2hPPG and HbA1c significantly further decreased by mmol/L, mmol/L and , respectively (p Sitagliptin 100 mg/day [n (%)] 77 () 74 () > Mean ± SD (mg per day) ± ± > All the antidiabetic drug(s) used before the study and their doses remained unchanged during the whole study. All the patients received sitagliptin at a daily dose of 50 mg or 100 mg that was unchanged until week 12. For weeks 1 to 12, and of the patients .

• Y khoa - Dược
• Type 2 diabetes
• Dipeptidyl peptidase inhibitor
• Oral antidiabetic drug
• DPP 4 inhibitors
• Type 2 diabetes inadequately
• Prevalence of type 2 diabetes
• Risk factors for type 2 diabetes
• Type 2 diabetes causes
• Associated factors of type 2 diabetes
• diabetes
• diabetes treatment
• diabetes prevention
• Oral Diabetes Medications
• Adults With Type 2 Diabetes
• Changing self care knowledge
• The outpatients with Type 2 diabetes
• Yenbai provincal hospital
• Type 2 diabetes for outpatient examination
• BMC Cancer
• Within class differences
• Patients with type 2 diabetes
• Cancer risk
• Weight gain
• Thiazolidinediones in type 2
• Type 2 diabetes mellitus
• TZDs exert weight gain
• Mechanism of TZDs on weight gain
• Diabetes mellitus patients
• Quality of life
• Life among out patients
• Type 2 diabetes managed
• QOL in this patient group
• Knowledge on the diet
• Practice on diet
• Outpatients with type 2 diabetes
• General information
• Drug use
• Agricultural Hospital
• Pre designed questionnaires
• Treatment of diabetes
• International Diabetes Federation
• Breast cancer
• Diabetes mellitus
• Female diabetes
• Cox regression
• Casein Kinase 2 Alpha 1
• Real time quantitative polymerase chain reactions
• Enzyme linked immunosorbent
• Protein complex
• Diabetes related protein complex
• Polyacrylamide gel electrophoresis
• Immunoinflammation related protein complexes
• Self care
• Self assessment questionnaires
• Diabetes self care
• Physical activity
• Risk factors
• Cancer development
• Diabetes duration
• Body mass index
• BMC Musculoskeletal Disorders
• Healthcare resource utilization
• Hospital claims database analysis
• Raloxifene hydrochloride
• Retrospective cohort study
• Prostate cancer diagnosis
• Gonadotropin releasing hormone agonists
• Prostate cancer
• BMC Geriatrics
• Myocardial infarction
• Impaired fasting glucose
• Glucose tolerance
• Laryngeal cancer
• C peptide
• Proliferative diabetic retinopathy
• Diabetic nephropathy
• Bariatric surgery
• Intensive insulin therapy
• Diabetes complications
• Glycemic control
• Retrospective study
• BMC Pediatrics
• Extract of Gingko biloba
• High fat diet
• Pancreatic β cells
• BMC Pharmacology and Toxicology
• Remogliflozin etabonate
• Sodium dependent glucose transporter 2 inhibitor
• Lower plasma glucose
• Tạp chí khoa học
• Tạp chí y dược
• Y dược quân sự
• Diet pattern
• Plasma leptin level